CEOInterviews.AI
Start App
Get an email when Robert Langer gives a new interview
One email per new interview. Unsubscribe in one click.
Robert Langer
Institute Professor, MIT

President's Lecture Series: Dr. Robert Langer

📅 Jul 18, 2025 Rice University 77 MIN 1136 VIEWS 147 SEGMENTS · 3 SPEAKERS
Dr. Robert Langer, a renowned scientist, engineer and professor at the Massachusetts Institute of Technology, gave the keynote at the recent President's Lecture Series on May 5. Often called the “Edison of Medicine,” Langer is one of the most cited engineers in history and has made pioneering contributions to drug delivery systems and tissue engineering, revolutionizing modern medicine. Beyond his groundbreaking research, he has co-founded numerous biotech companies, including Moderna, the company behind one of the first COVID-19 vaccines, translating scientific discoveries into life-changing...

Questions asked in this interview

9
  1. 58:25And what advice would you give to particularly the young faculty getting started with balancing those two things?
  2. 1:00:27Could you talk a little bit about that and how that's worked out?
  3. 1:02:05What was your reaction seeing your foundational work play such an important role around the world?
  4. 1:03:35Talk a little bit about your philosophy with mentoring and why so many of your people that work with you are leaders themselves and doing incredible things. How did you do it?
  5. 1:05:41I know this group is not a shy group. And where are the mics?
  6. 1:06:04Was that the targets and mechanisms?
  7. 1:08:08Why did you revise 'never give up' to 'never give up almost'?
  8. 1:10:52How do you inspire your students to find the great questions to ask?
  9. 1:15:06What encouragement do you offer scientists in these days where vaccine hesitancy and even germ theory are being questioned?
Host 0:01 ↗
Good morning, everyone. Can you hear me?
Good morning, and it's a pleasure to welcome you to the President's Lecture Series here in the beautiful Brockman Hall for Opera on an equally beautiful day here on Rice's campus. Over the years, this series has brought a variety of stimulating speakers to the Rice stage. Our last speaker, which actually was several years ago, Eric Yuan, the founder and CEO of Zoom, spoke via Zoom during the COVID-19 pandemic about the evolution of the virtual platform. Rice alumni Dr. Barney Graham and Bill Gruber gave a lecture about their personal involvement in the creation of the COVID-19 vaccine, and several Nobel Prize winners, authors, business owners, and pioneering leaders in higher education have given keynote addresses on a wide range of topics. Their knowledge and experiences have enhanced the intellectual life of the Rice community and of our neighbors throughout the city of Houston.
Today, we are honored to host Dr. Robert Langer, a renowned scientist, engineer, and professor at the Massachusetts Institute of Technology, better known as MIT. He is often called the Edison of medicine. Dr. Langer is one of the most cited engineers in history and has made pioneering contributions to drug delivery systems and tissue engineering, revolutionizing modern medicine. He has mentored thousands of undergraduates, graduate students, and postdocs who are, in their own right, stars around the country. Several of them here at Rice University. A graduate of Cornell University with a bachelor's degree in chemical engineering, Dr. Langer went on to earn his Doctor of Science in chemical engineering from MIT, where he holds the title of Institute Professor, the highest honor awarded to an MIT faculty member.
Over the course of his extraordinary career, Dr. Langer has received more than 220 major awards. So, let me repeat that: he has received more than 220 major awards. It's not a typo, and I promise not to mention all of them, including the United States National Medal of Science and the National Medal of Technology and Innovation, two of the highest honors bestowed by the US government. He is also a recipient of the Queen Elizabeth Prize for Engineering, the Breakthrough Prize in Life Sciences, and the Charles Stark Draper Prize, and most recently the 2023 Priestley Medal, the highest honor of the American Chemical Society.
He is one of only a few individuals ever elected to all three academies: the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. A testament to the breadth and impact of his work. It's just a coincidence that Rice has had its first trifecta this past week when Professor Lydia Kavraki was elected to the National Academy of Science, giving her that same great honor, our first in Rice's history. Dr. Langer's work exemplifies the profound impact that interdisciplinary research can have on society. His innovations have not only advanced scientific understanding, but have also led to practical applications that improve lives. His co-founding of Moderna, the company behind the first COVID-19 vaccines, demonstrates how scientific discoveries can be translated into lifesaving therapies.
As we continue to navigate the challenges of the modern world, the importance of such translational research cannot be overstated. It is through the dedication of individuals like Dr. Langer that we find solutions to some of the most pressing issues of our time. Please join me in a warm Texas welcome for Dr. Robert Langer.
Robert Langer 4:02 ↗
Thank you so much. It's a tremendous honor to be here today and to see all of you. So I'd like to tell you a little bit about my career and what we've tried to do. So the lecture I'm going to give is a little bit different than a lot of them I do, which are purely academic, but because what I'm also going to try to go over is how we took those academic inventions or discoveries and worked with others to create companies to create products, like you just heard in that introduction. So I actually entitled my talk "The Road Not Taken," which is named from a Robert Frost poem, because as you'll see, I didn't really do exactly what a lot of other chemical engineers did. But I thought I'd make a summary slide of part of what I was going to discuss, which is innovation.
And this is sometimes what I tell my own students: is to do things that you hope will have a very big impact, as opposed to incremental research. That might seem like a very straightforward piece of advice, but it isn't. You know, what if people often go into academics, you know, the way they get judged might be their grants or their papers. And if you do something incremental, you can certainly get a paper, and those papers will help you get grants.
Same thing in companies. If you go out to work in a company, a lot of people, I mean, there's nothing wrong with this, is you want a secure life, and so it's much easier to do, you know, something where you know you're going to get paid and you're not going to change the world. But I think that if you want a certain degree of satisfaction, you know, maybe it's taking risks. Second thing I was going to say is conventional wisdom. What you hear and sometimes read in the textbooks, it's not always correct, and challenging that can be important.
The third is something I call convergence. At least for me, it's the idea of being exposed to very different disciplines. I think it's something we're even seeing a little bit in academia now, in the sense that for years, like when I was in college, there was a building for English, a building for math, a building for chemistry. Now sometimes people get put together and they learn things from students and professors who have very different backgrounds from their own. The fourth is to take risks and realizing that it's okay to fail. I think that's one of the great things about American culture. You know, I'm not a fan of Hershey. I love chocolate, as some of my students know. I'm not necessarily a fan of Hershey's chocolate, but I love the story of Milton Hershey, who had this dream very different than my own, but his dream was to start a candy store, and he tried about eight times and he failed each of those times, but not the ninth.
Fifth is if your idea is important, expect lots of criticism. And six, I used to say never give up, but now I say never give up almost. So with that, let me tell you a little bit about how I got started and my struggles and my dreams. So the way I got started, I got my degree from MIT in chemical engineering in 1974.
And that year there was this gas shortage, and what happened if you lived in the Boston area where I did, you had to wait in line for two hours to get your tank filled up. But the consequence of that is that if you were a chemical engineer, you got a lot of job offers. So pretty much all my friends, they went to work for oil companies. I thought I'd do that too. So I interviewed. I actually got 20 job offers, four from Exxon alone, including Exxon. I think there was one in Baytown and one anyhow. But believe me, I wasn't that good, but they just had so many openings. But you know, when I flew back to Boston, I think about what I was sometimes asked to do, which was increasing the yield of certain chemicals by small percentages. And I just thought to myself, I didn't want to spend my life doing that. I didn't know exactly what I did want to do, but I thought, I want to do something that would help people. And when I was a graduate student at MIT, and I was supposed to be doing my thesis, I got very, and I did some, but what I did is I helped start a school for working-class and low-income high school students. And I got very involved in creating new chemistry curricula and new math curriculum. And one day I saw an ad from City College of New York to do just that. So I wrote them a letter applying for a job, but they didn't write me back. But I really liked that idea. I found all the ads I could to do something like create new chemistry curriculum as an assistant professor. I found about 40 of them and I wrote them all, and I don't think any wrote me back. So that wasn't so good. So I started to think what other way could I use my chemical engineering background to help people? And I thought about medicine. So I wrote to a lot of hospitals and medical schools. They didn't write me back either. One day, I remember walking into the lab where I was at MIT, and one of the older scientists said to me, he said, "Bob," he says, "there's a surgeon in Boston named Judah Folkman." And he said, "Sometimes he hires unusual people."
He thought very highly of Dr. Folkman. I won't say what he thought about me, but Dr. Folkman had this idea that tumors, this actually was from the New York Times in the early 1970s, but he had an idea which at that time was very controversial, but basically saying that tumors grow because they get blood vessels and they even secrete chemicals which he called tumor angiogenesis factor that cause the surrounding blood vessels to actually grow when they normally don't at all. But they grow and they grow and they feed the tumor and the tumor gets bigger and bigger. And if you go to the top of that slide, you can see how vascularized it is diagrammatically. And of course, what often kills people is spreading through those blood vessels and setting up in other places. That's a process called metastasis.
So it turns out, as I mentioned, that many biologists didn't believe this. Since I knew almost no biology, I thought it sounded quite good. But at any rate, he hired me. He said, "Well, Bob, your job is to prove I'm right, and in so doing, could you isolate the very first substances that could stop blood vessels from growing?" Now, the thing is, if you work in an area like this, like finding a new factor, the biggest problem, if you look back on this historically, is having what we call a bioassay to study that. And there wasn't one to study blood vessels. And it's not easy because wherever you go in the body, usually there are background blood vessels, but there's a few places in organisms and people where there are not. One is the cornea, and two is what we thought is what's called the chick chorioallantoic membrane. That's from a chicken. So we had an idea that we would create a bioassay by putting certain tumors, for the biologist that was a V2 carcinoma, in, let's say, the cornea, and that would cause blood vessels. But what we would want next to it is basically a little delivery system, a nanoparticle or microparticle that could deliver any molecule we want to isolate. And Dr. Folkman's theory was that the molecules we wanted to deliver were very large, like proteins or polysaccharides or nucleic acids. Now this was 1974. In 1974, the area of advanced drug delivery systems was almost non-existent. There was only one company in the world, a company called Alza in Palo Alto, California, working on this. They had no products, but they would later commercialize what are called transdermal patches, and they had Nobel Prize winners on their advisory board in chemistry. And so Dr. Folkman went out there and he asked them, could they help us?
But they all said, "Well, no, you know, maybe you could deliver a small molecule, but you'd never be able to deliver a large molecule because they would be too big to pass through, you know, the walls of a tiny particle, just like none of us will be able to walk through that wall." But if we were going to solve the blood vessel problem, we had to solve this delivery problem. So I spent several years working on this, and I actually found over 200 different ways to get this to not work.
But eventually we were able to make these tiny particles. You see a picture of one and one cut in half, and I'm sorry. Yeah, you see a picture of one and one cut in half. And what we were able to show, and we published this in the journal Nature, is that if you put different large molecules in them, you can deliver them. This was 49 years ago, and in fact, this is the very first paper that shows that you can actually create tiny particles to deliver nucleic acids. For reference, DNA and RNA are nucleic acids. So I remember this, you know, I got asked in 1976.
This was three months before this paper came out to give a major talk for the first time in my life. I was 27 years old. I practiced this talk for many weeks. Finally the day came. It was in Midland, Michigan. I got up and I gave the talk, and it was, like I say, 20 minutes, and I thought at the end of it I did okay. I didn't forget too much of what I was going to say. I didn't stammer too much. So I thought when I was done, all these older scientists being nice people, I can tell it's the scientists who are laughing, because they know. And I thought they'd want to encourage me, this young guy. But when I got done, I stepped off the podium and a whole bunch of them came up to me and they said, "We don't believe anything you just said."
They said that the molecules again were too big and the solvents that we were using like ethanol or methylene chloride, they destroy whatever we put in. And things actually went downhill from there. I tried to get research grants, you know, you write your grants to like National Institutes of Health and places like that and they have study sections and they review them. My first nine were rejected and they weren't just rejected. They were pretty firm about how bad I was. One of them said, "I remember Dr. Langer is an engineer. He knows nothing about biology and even less about oncology."
I thought I knew enough about math to know that was pretty hard to do, but it didn't really matter. So I didn't do very well on grants. And then, you know, I loved being a postdoc at Boston Children's Hospital and Harvard Medical School. I was actually the only engineer there. I learned so much. But a lot of my friends would tell me, you know, maybe I should, you know, get a real job someday. And so I did. I started applying for faculty positions in 1977. And I had applied to chemical engineering departments because that's my background. And no chemical engineering department in the country would offer me a job. They actually said the opposite of the study section. And they said, well, you want to do this bio stuff, you should be doing, you know, energy or mathematical modeling or, you know, stuff like that. And anyhow, so I didn't get any jobs there. Finally I got a job actually in a nutrition department, and the reason I think I got it is the guy who was the head of that department, Nevin Scrimshaw, very famous nutritionist, but he was what I'd call a benevolent dictator kind of department head, meaning he liked me, so he offered me a job, but he didn't ask anybody else in that department, any of the professors, what they thought.
Now that might have been okay except for one thing, which was the year after I joined the department, he left.
So a lot of the senior faculty decided to give me advice, and their advice is I ought to leave too. And this is true, you know, one of my good friends at the time and still is, Mike Marletta. Mike later would become head of Berkeley's chemistry department, the head of Scripps. And about 15 years ago, I got an award and they asked if he'd say a few words. So I excerpted this from his talk. He was referring to 1979. And what he says is one evening he went to a faculty dinner at a Chinese restaurant with me and some senior MIT professors. He said, "A senior scientist sat quizzing us while smoking a cigar." He said, "When the elder scientist heard my concepts for drug delivery, he blew a cloud of smoke in my face and said, 'You better start looking for another job.'"
Fortunately, I'm still at MIT. But it was a kind of not easy beginning. But since we had developed the drug delivery systems, now we could do the bioassay that I mentioned. So I'm going to show you a fairly graphic picture. There's no other way to show blood vessels, but so if anybody doesn't like blood, don't look. But what you're going to see is from a paper in Science we wrote in 1976, which does show for the first time that diffusible substances can stop blood vessels from growing. So I will show it rather quickly.
And here you see on the left the sheet, what this is, what you see in a control. We did probably 2,000 of those because I had almost every fraction we tested didn't work. But on the right you can see that you can get inhibition, and that would show both those things that he wanted. It shows that those molecules would exist and it would provide a pathway for all future inhibitors to be found. Now medicine, as a lot of you may know, it doesn't move fast. We published that paper in 1976. As I mentioned, it took 28 years and literally great work from companies like Genentech and spending billions of dollars using a lot of the approaches we developed, but it took them 28 years before the first blood vessel inhibitor would get approved. But starting in 2004, and this may be hard to see in the back, it doesn't really matter. The point I want to make is there are a lot of them now. But starting in 2004, Avastin gets approved. Avastin is the number two or three best-selling biotech in history. Even last year, 20 years after its approval, was the number four best-selling drug in the world. And you can see on this slide that there are many, many blood vessel inhibitors approved for literally all kinds of cancer. And not only are these used for all kinds of cancer, they are the only pharmacological entities that can be used to prevent diseases of blindness in the back of your eye. Diseases like macular degeneration, which is the leading cause of blindness in our country, or diabetic retinopathy. All these drugs have become, you know, blockbusters, multibillion-dollar-a-year drugs. And Nature, the journal, estimates it'll be used by half a billion people worldwide.
I want to go back though to the 1970s. Not this, you can see this keeps going on to today. Going back to the 1970s, you know, Dr. Folkman and I talked about, well, maybe we should write a patent. You know, now I have quite a few patents, but then I had zero. And Children's Hospital in Boston, which is a very good hospital, we had zero there too. So we wrote a patent, five years in a row it got rejected. So I remember Al Brazzolini, the head of the tech transfer office at that hospital, coming to see me one day. He said, "Bob, you're wasting so much money for the hospital on these patents. They're never going to allow it." He said, "Just quit." But that was one of my things on the first slide. I don't like to quit. So, but I started to think how could we convince the patent examiner to allow our patent, legally, of course.
And science really wasn't working. But when I mentioned this to you in the beginning, I told you that all these people we talked to said this was impossible. It could never work. I wondered maybe somebody wrote that down. So what I did in 1982 is do what's called a science citation search, meaning I looked back to see who cited our 1976 Nature paper and what they said, and I found some interesting papers. I will just show you one, and this is from five of the top material scientists in the world. I had no idea it was written. I'll just read it to you. They're describing this field, and they said, "Generally, the agent to be released is a relatively small molecule with a molecular weight no larger than a few hundred. One would not expect that macromolecules could be released because of their extremely small permeation rates. However, Folkman and myself have reported some surprising results that clearly demonstrate the opposite." So I really like that word surprising. And I showed it to Dr. Brazzolini. He flew it out to Washington to show it to the patent examiner. And the patent examiner said, "Gee, I had no idea." He said, "I tell you what, I will allow this patent if Dr. Langer can get written affidavits from each of these five people that they really wrote that."
It's a true story. And by the way, if you ever want to get patents and you get your grants rejected, you save the quotes. At any rate, so I did. I got, they're all, I was an assistant professor. I wrote them and they were all nice enough to write me back. They really did write it. We got this really broad patent. So now I'd been working on this for about 10 years. You know, like I said, I had this dream. I wanted something that I did to make a difference. And I finally got calls first from one multibillion-dollar company in animal health and then just a bit later a second one in human health, and they said, you know, we read about your work, would you consult for us? We'd like to give you a big grant and we're going to develop this. And I was so happy about that, but you know what happened is I did get a better car. I had a Ford Pinto at the time, but at any rate, what happened is each of them worked on it for about a year and then they gave up. They didn't get exactly the results they wanted. So Alex Klebanov, one of my good friends, he said, "Bob, we should start our own company." So with four of my students, we started this little company and I got the patents back. We started this company. We did this merger with our next-door neighbor, Alkermes, and the company is still around today. They have 25 products that are FDA approved or in clinical trials. New treatments for schizophrenia, alcoholism, opioid addiction, type 2 diabetes.
Just to show you some pictures of some of these products and other things that came from our lab, either because of our patents or because of helping companies using principles we developed. I made this slide, and you can see, I mean, there are many different things on here. Lupron Depot in the middle, we worked with TAP, that's a treatment for advanced prostate cancer. That's delivering a peptide that's nine amino acids. If you try to swallow it or take it nasally, you just don't get any in the blood. If you inject it, it's destroyed almost immediately. So now they put it in little microspheres. Originally they lasted a month. Now they last six months, and it's one of the world's largest major ways of treating advanced prostate cancer and endometriosis. But there are many, many other ones up here. Vivitrol is one of the most common treatments for opioid addiction. And there's other treatments for schizophrenia and up here and so forth. Not only are they useful in medical things, on the bottom right, they turn out, Yonathan Zohar, who is one of the world's experts in aquaculture, came to visit me, and what we did is we started making little implants that are used to control spawning and actually even used to preserve rare fish, and that would end up helping make aquaculture a quarter-of-a-trillion-dollar industry.
So because I had started a company and we were doing this kind of work in chemical engineering, which was now much more experimental than just theoretical, you know, I'd get more and more students and postdocs coming to me. So I'll tell you a second story. This is David Edwards. David Edwards, actually, when he came to our lab, he had written two books with Howard Bremner and he had published 30 papers. He had never done an experiment in his life. But what he did was a lot of mathematical modeling. One of the things he modeled was the lung. So when he came to our lab,
I told him I thought we could really do something in the aerosol area. Aerosols, which would be another drug delivery vehicle, are incredibly inefficient. You're lucky if you take an inhaler and you get 2% from the device into the lung. You might ask why. Well, people always thought aerosols had to be really tiny. They thought if they were big that they'd settle in the back of your throat, but if they're tiny, it's kind of like wet sand, right? There's so much surface area, they'll stick together. They'll stick together in the device, in the air, in your mouth. So very little gets to the lung. So how did people try to change that? Well, they designed better and better devices to break apart those sandlike aggregates, and they, you know, aerosolizers, and that would enable them to go from 2% maybe to 3%, which is still not much. The problem with getting so low efficiency is not just the cost, it's also that for many drugs you'd have to have a giant inhaler.
So, anyhow, nobody ever really tried to change the aerosol. I mean, everybody kept trying to change the inhaler, the device. So what David and I started talking about was, well, at this time, this was now the early 1990s, almost all the inhalers were metered-dose inhalers or nebulizers. You're, you know, nebulizing basically water. There were a few what are called dry powder inhalers, but the density of whether you're dealing with water or the dry powders in that case, they were always roughly one gram per cc, and we'd call that a non-porous aerosol. And so what David started doing is mathematical modeling. So what if we made these aerosols really big but incredibly porous? They will not stick in the back of the throat. They will end up going into the deep lung. There's something called an aerodynamic diameter. So what we decided to do is make large aerosols but incredibly porous ones. And the hope would be that they wouldn't stick together, like wet basketballs aren't going to stick together like wet sand. There's just much less surface area. Also, we thought they might last longer because macrophages, when you get in the lung, there are cells that like to eat these aerosols. It's kind of like rather than eating a small meal, which doesn't take you long, now what the cell sees is this big meal. So that might take longer. These were our theories. So we made some of these, and I'll just show you a picture, and I'll give you a sports analogy. So before we were involved, if you ever looked at an aerosol, it might look like a little golf ball or a little baseball. Now they look like whiffle balls. It's really that simple. But that change in geometry changes everything. If you go to an in vitro experiment, what you see is you can actually, on the right-hand side, get 10 times more in. If you go to an in vivo experiment using what's called forced inhalation, you can again get about 10 times more in. And if you do, this is published in Science, if you do a human experiment, you can actually make these last for three days. So again, we filed the patent. I won't keep showing you all our patents, but basically this patent is one of the things we kept doing because it was important to have broad patents to raise the kind of funding we needed to get these to people. I should add, when we tried to write our grants on this to the National Institutes of Health and other places, they were soundly rejected. People said this wouldn't work. I got used to that. But at any rate, just to show you what the claim is, it's a particulate system and the particles have a density less than 0.4 g per cc. Normally they're about 0.1 gram per cc, but they're much bigger than ever before. And notice that the claim is for any agent. So we started this company, we called it Nektar, in 1996.
We published the paper in Science in '97. We started Nektar with a whole bunch of our students in 1998, and Terry McGuire at Polaris gave us a quarter of a million dollars to start it and did the business development work where we'd make deals with Lilly, Glaxo, Pfizer, and actually started two clinical trials. It was easier to start the trials because all we did was change the geometry. We didn't change the chemistry, and you know, about four companies wanted to buy it, and David, who was really running it, he didn't want to run it forever. So we did sell it, and this is one of the highest returns, I guess, in the history of biotech. We also were able to, you know, a lot of people always say that patents are, some people say patents are bad, but if we didn't have the patent, we would never have made the progress that we made because we wouldn't have had the funding. And David actually spun off a nonprofit to make these aerosols for the developing world. Anyhow, and the technology kept going through different places and ultimately gets FDA approved now, and the principles, of course, widely used. But I just want to show you, this is actually approved, it's Arcapta Neohaler, and this is the little device that you can have, and it fits in your hand. Normally the device this size could not aerosolize more than 2 milligrams. This aerosolizes 70 milligrams just because of the principles that I mentioned. So that's another example that I wanted to go over with you. I'll give you a third.
So if you look at biomolecules, you could think that there's almost maybe three different classes. Proteins, which are monodisperse, right? If you have insulin, all insulins are 6,000 of the same structure. Nucleic acids, they're similar. Polysaccharides like heparin or glycoproteins, they are polydisperse. In other words, if you took heparin, which is a blood thinner, it's very commonly used, or any glycoprotein, you're actually taking a mixture even though the whole thing is approved. So with two of my students, we also had this idea of creating what we call the first glycomics company. And the reason we were able to do it, and again, I'm going to go through the science at a very high level for this, is since you have a mixture, right? Let's just take heparin. You have a mixture and it gets, but the whole thing gets approved. So that would mean that theoretically anything in that mixture probably is reasonably safe at a certain dose. So our thought was, what if we could fractionate that mixture and find what we call a glycoform? In other words, every molecule in that mixture would be a glycoform. But we came up actually with the very first time that you could sequence polysaccharides. People had by this time sequenced proteins. They had sequenced nucleic acids, but polysaccharides had never been sequenced. The reason we were able to do it is I had done work creating what we'll call molecular scissors like heparinases and heparanases that was published in Science in 1982. And so you could take these polysaccharides and cut them in specific places. Then you could take those cuts and use mass spectrometry to characterize their structure. And then Ram and Ganesh, they created an algorithm, also published in Science in 1999, that could put these cuts back together. So that gave us the ability to really understand the structure of any of these and could lead to potential products like heparins, other complex polymers, or new glycoproteins.
So again, since my students saw I started a company, and we started others too, and David started it with me, they wanted to start a company. So we did, and this is Momenta, started with two students. We got venture capital from a variety of groups, went public in 2004. One of the things, not that I want to give a business lecture, and I'm not a very good business person, but I've worked with a lot of good business people, which by the way is far, far more important. Just as an aside, if you ask me later what is the important thing for success of a company, it's actually not somebody like me, it's actually having a great management team and a great CEO. I could help get it started, but anyhow, coming back to what we do is we would take pieces of what we've done, because you can do this with any polysaccharide or glycoprotein, and we would make deals with different large companies to help finance it further, and they would have the marketing rights to those. And so that's what we did. We got major deals with Novartis, with Baxter, with Organon, with CSL, and because we had enough funding, we could actually sequence all these things. And in 2010, we got the first Lovenox biogeneric approved by the FDA. It was actually the first complex drug ever approved just purely on analytic data, and it was the largest syringe launched in history. I should tell you that the stock analysts all told us that would never happen, that Octava and many other bigger companies would beat us. Of course, still today, now 15 years later, they haven't gotten it approved, but still that was what you'd hear. And ultimately, Johnson & Johnson acquired the company even for some future things, like because you can now use this, like they're working on treating myasthenia gravis with some of the products that are coming from Momenta. So they acquired it for $6.5 billion. Just to show you some pictures. This is the product. The company did well, of course, when they got the FDA approval.
But I want to tell you one other story, and that is in 2008. People may or may not remember this, but there was this giant heparin crisis where a lot of people would die. This is just a few headlines. It came from China, and I once was the head of the FDA Science Board, and Ram, my student, had worked with them as well. So they called us up and asked could we help. So we actually worked with Momenta, the company we started, the FDA, and the CDC, and we published three papers the same year, actually. The first one in Nature is at the bottom, shows what the contaminant is. The other two in the New England Journal, like I say, was a company, FDA, and CDC. I had never seen that before. And MIT actually, after this, there were no more deaths. So that was a great example of how this kind of cooperation can make a giant difference in patients' lives.
You know, the next example that I want to give you builds on the first. You know, when you go back to our 1976 Nature paper, I mentioned that you could use that approach to make tiny particles. You can really make them of any size. But when you make them extremely small, like a nanoparticle, they can stick together, right? So working with Vladimir Torchilin and others, we showed that you can take a substance in Miralax. This is polyethylene glycol. I don't know if any of you take Miralax. Older people like me might, you know, helps you go to the bathroom better. But at any rate, it's super hydrophilic. You can dissolve it in water, and so one of the thinkings about it is that if you put this on the outside, we'd make these what we call diblock materials. If you put this on the outside of a particle, hopefully it will solve the problem of aggregation, and also because it's water-like, the macrophages, which I mentioned, eat these particles, they won't eat them nearly as fast because it's like a disguise, just water. You can even go further. Omid Farokhzad, when he was in our lab, put targeting molecules on these, and another company I was on the founding scientific advisory board of, Alnylam, would use this kind of approach to deliver the first siRNA molecules, which would lead to Onpattro. This was done actually by Akhilesh Kinkar, one of my students, who worked there for a number of years and led that project. I thought sometimes I don't explain this part that well. So it must have been about 12 years ago, maybe 15 years ago, NOVA, the TV show, they came to our lab and they filmed a video called "Making Things Smaller," and they spent about seven or eight minutes on our lab, and they made a video which explains this far better than I ever could. So I will show you it.
Narrator 37:08 ↗
He starts with a nanoparticle of anti-cancer drug that gets encased in a plastic that releases the drug over time. That in turn gets a special disguise that packages the package as a water molecule to the body's immune system. And last but not
Robert Langer 37:25 ↗
At least, he addressed where it should be delivered—a key that will only fit a lot of cancer cells.
I should tell you that the clinicians I work with tell me it doesn't really blow the cell up quite like that. But you get the idea, and that did open the door to delivering molecules like siRNA and, as I will tell you now, messenger RNA, because if you didn't have them, these molecules would be destroyed.
So in 2010, working with Derek Rossi, Nubar Feyman, and Ken Chen, we had the idea of creating messenger RNA therapeutics. And the idea of messenger RNA is, let's say by this time proteins had become, you know, really some of the major drugs in the world. I think right now something like 14—sorry, 18 of the top 20 drugs are large molecules, but they take a long time to make, and that means you're going to guess sometimes.
A great example is flu vaccine. People have to grow up eggs. They have to start a year or two in advance, and they guess: are you going to have H1N1, H1N2? They don't really know. That's why flu vaccines are about 40 to 50% effective. But if you took messenger RNA, all you'd have to do—and I'll—is to create the messenger RNA, put it in a nanoparticle, inject it in a person, and it'll do the same thing.
So not only that, you could use it to treat diseases that never had been treated before, because you could make new intracellular and membrane-bound proteins. So we started Moderna in 2010. Nubar was chairman, I was on the board of it, and Derek and Ken were advisers.
And what we did is—and all the stock analysts and news writers would criticize the company that said it wouldn't work—but by the end of 2019, we had 13 products in clinical trials, eight of which were vaccines. And then, as you know, COVID hit. I just want to show you what the Moderna scientists, a number of whom are our students, were able to do.
In 2020, the Chinese scientists published the spike protein on the virus genetic sequence. It took less than two days for the Moderna scientists to design the vaccine, put it in nanoparticles, ship it to our clinical partner, the National Institutes of Health, for testing, and the first patients were treated in March, you know, just two months later.
And by the end of the year, you're doing double-blind studies, meaning nobody knows who got what. Well over 30,000 patients got treated, and it was approved for emergency use authorization all over the world.
If you look at some of the data, I'll just go through it quickly. You can see the enormous difference. I want to show real data, not just tell you. What you see is if you compare unvaccinated to vaccinated or plus a booster, you get this. If you look at effectiveness, this is from the Mayo Clinic, one of the top hospitals in the world. The Moderna vaccine is 94% effective. The Pfizer—this is just in the US—91% effective.
Johnson & Johnson had a de novo viral vector, which they ultimately would pull off the market. From JAMA, these are all the top medical journals. Over six million patients that are old like me, over 76, you can see it's the safest, most effective vaccine.
You know, there are certainly—I'm sure people know this—people that don't believe in vaccines. But if you really go to any public health agency in the world, there's been so much data accumulated over hundreds of years that pretty much anybody will tell you, if they've looked at that data, that the vaccines are the most effective public health tool ever created.
So maybe even a better question about whether vaccines are safe or not is: if you take a new kind of vaccine like an mRNA vaccine, how does its safety compare to an existing vaccine like a flu vaccine, which has been used for many years? And if you look at that again from published data, what you see is the overall safety profile shows a lower risk of serious adverse effects following immunizations for the mRNA vaccines compared to flu.
And if you look at it, it wasn't an easy thing to do. This is from Forbes actually, but they show that there's 49 failed vaccines, two approved. This is as of 2023. For treatments, 209 failed treatments, one approved, which is Pfizer's. Antivirals, 153 failed, one approved.
If you look at various economic analyses, this is from the Commonwealth Fund, you see that over an 18-month period it prevented three million deaths, 18 million hospitalizations, 120 million infections, and saved the US 1.5 trillion dollars.
And to me, this is really the tip of the iceberg. I think certainly one of the worst diseases that anybody can have is cancer. And let me just show you how the very same principles can be applied to that. This was basically already announced by Moderna and Merck. It's what's called the phase two trial. So it's not ready for anybody to use. It's now in what's called the phase three trial, which is the final trial.
But in the phase two trial, if somebody had melanoma, late-stage melanoma, what you did here—there's 157 patients with melanoma—and you're going to do a double-blind study. But in the case of COVID, the idea is you make the vaccine to train a body that's going to attack an incoming virus, and it attacks it and hopefully kills it. If it doesn't kill it, it'll certainly lower the dose so you don't get as bad a reaction.
That's the same idea that we're using here, except for one difference: you already have the cancer. So you know you have the melanoma. So now you take their top 34 mutations. So rather than go after the spike protein, you go after the top 34 mutations. You take their genetic code, you make an mRNA—you take the genetic code of those neoepitopes and you incorporate it into the mRNA the same way it was done with the COVID vaccine. You put that in nanoparticles.
And then what was done in this trial is half the patients get—it's again double-blind—half the patients get Keytruda. That's Merck's, you know, great immunotherapy drug. It's the largest. In fact, some of this is based on Jim Allison's work at MD Anderson. But half of them get Keytruda, half get Keytruda plus this personalized vaccine or individual neoantigen therapy.
And you can see two years the risk of recurrence or death is reduced by 44%. Three years, 49%. Metastasis reduced by 66%. And we've continued, you know, now it's in many different clinical trials.
And actually in our own lab, working with the Gates Foundation, we're working on ways of giving single injections of vaccines so that—in fact, Kevin McHugh, who's a professor here who was a postdoc with us, actually led all that. So hopefully someday, for any disease, maybe you'll just need to get injected once.
I was going to shift gears a little bit and tell you something else I learned while I was at the hospital. Being a chemical engineer, I was very curious: how did materials find their way into medicine? Was it other engineers or chemists, or was it doctors? And what I noticed is pretty much every time that these things were done, the doctors would take—when they wanted to develop something, they took something from their house that kind of resembled the organ or tissue they wanted to fix.
So the artificial heart—they wanted something with a good flex life. So they asked, well, what object has a good flex life? And they said a lady's girdle. So that's what they made in 1967, the artificial heart out of the lady's girdle, which is a polyurethane. But you know, it did get approved, but one of the big problems with it is when blood hits the surface of it, it forms a clot. If that clot goes to the patient's brain, they get a stroke and they die.
Yet, if you think about it, something that was designed to be a lady's girdle may not be the optimal blood-contacting material. And this problem goes through all of medicine—breast implants, one of those was actually a mattress stuffing.
So we thought, well, there's different materials that we could make based on scientific principles, and maybe we could even make tissues or organs from scratch. So Jay Vacanti is a surgeon, a good friend of mine. This is a little baby who he treated, and he came to see me around 1980 and said, 'Bob, could we ever make tissues or organs from scratch?' So we came up with this idea where you could take virtually any cell type.
Now, you could also take stem cells. But when we wrote this paper, you know, that was before people even did anything with them. But you could take any cell type, you know, inject it at random, nothing happens. But cells are smart. And when you put them on these scaffolds close enough together and grow it under the right reactor conditions, maybe you could make bone, cartilage, whatever you want.
So I'll just show you a couple quick examples. Here's a scaffold with cells. And let's say a little baby is burned. So here's a two-year-old boy, badly burned. But now you can take the product, which are neonatal skin fibroblasts, on a polymer scaffold. You can even cryopreserve them. You can put it in the child at the time of injury.
Let's come back three weeks later, and six months later it's pretty much healed. These are now approved for patients with diabetic skin ulcers and burns also.
You can even make tissues and organs on a chip. Gordana Vunjakovic and Milica Radisic—they're professors at Columbia and Toronto today, but they were a postdoc and graduate student in our lab—and they made a heart on a chip. You could actually put heart muscle cells in with the right media and everything and get the cardiac-specific ultrastructure, and you can even take a video.
And here's a video. There's actually six million heart cells, and we're not shaking this or anything—they're just beating. You can even take an EKG of them, and it's pretty authentic. And Milica and Gordana actually started a company to do drug testing of this, which is working with 20 other companies.
And over the years, people from our lab and elsewhere—in fact, Tony Mikos is a great example of this, who's a professor here—made many, many contributions to this, so that you see all kinds of tissues and organs up here. Some are in clinical trial, some are approved, some are organs on a chip.
Maybe just to highlight a couple things. Laura Niklason, who was one of my postdocs who went to Yale, started a company to make blood vessels from a paper we wrote in Science in 1999. Last year they were widely used for all Ukraine soldiers who were wounded, and the FDA just approved those blood vessels about three months ago. And then we're actually working on brains on a chip.
I also wanted to highlight pancreas. This was work actually that Omid Veiseh did when he was working with me, and Dan Anderson did, and Paul Wooten has been very involved. I was initial CEO of a company we started, and we're continuing to work on it with them.
So I thought I'd give you one last example of what we do, because I realize maybe not everybody in this audience is interested in medicine. So I thought I'd tell you one other story, and that's hair.
So one of the venture capitalists, Amir Nashad, who was one of my students, was at Polaris, and he said to me, 'But Bob, you know, we've funded all these companies to help you do medical things, but we were interested in starting a hair company.' I said, 'Well, what kind of thing did you want to solve?' He said, 'Well, when we talked to hair stylists, they said a lot of people like me probably have frizzy hair.' So they said, 'Could you come up with a way to stop that?'
So we started this company, Living Proof, with again some of my students. And when we looked at this, you know, you always want to take a scientific view. So what did everybody else do? There were actually, when we started this in 2005, many companies creating no-frizz products, but everyone did exactly the same thing. They used the same ingredients, silicone, like silicone oil.
And they formulated it differently, right? Different fragrances, different amounts of other things. But actually, when we examined this, we wanted to figure out what is the mechanism of getting frizz. Well, you probably all know, right? It's probably humidity. And how well does silicone keep out humidity? Well, not very well.
So what we started to think about, working with Dan Anderson, who was a postdoc in my lab and now a professor at MIT and also an adviser to Living Proof, what we started thinking about is: if you're going to keep moisture out, what's the most water-repellent thing you could think of? And so a lot of people might say silicone or oils, and I sometimes give this a quiz, but I won't do it today.
So the most thing we could think of was something like a Teflon frying pan, but of course you don't want to put that in your hair. But you could look at its chemistry, which was a polyolefin, and we found one that was FDA approved for coating, you know, intraocular lenses, and that actually worked quite well.
So the company created these, and they're all over the place, like in Sephora stores and other stores today. But basically, that's it. And I thought I'd just show you a video from TV about this.
Narrator 51:37 ↗
It's a complete no-brainer. MIT treats Anderson research labs in the country, alone in the world.
Now their work on stem cells had to make another vexing. The result of science has taken the beauty by storm.
It's so amazing that the big companies haven't been able to solve these problems in such a short time. We've been able to. [Music] CEO, Living Proof. This startup's secret weapon: science, using outside the beauty industry. [Music]
Notice Mr. Langer is a co-founder of Living Proof. Until now, it has relied on silicone-based products, which keep moisture out but leave hair heavy, greasy. Along their discovery. [Music] Equal opportunity problem solvers.
Robert Langer 54:05 ↗
Now the company's found even some better ingredients, but they asked us other questions. Well, could you give hair more body? So Dan actually, when—and Dave Lynn, when they were in our lab—created a family of polymers called poly(beta-amino esters), and so we had these giant libraries of them which we were looking at for gene therapy. But since you have composition of matter patents, you could use them for anything.
So we found one that actually could give hair more body. And then what the company did is they sold that, and actually they came up with different products. They'd mix the two together. Then they'd call it PhD—Perfect Hair Day.
But I did want to say, actually, marketing ends up—and they have like 50 to 100 products now. But you know, I remember we hired this woman, Grace Ray, who was head of marketing. She was at Harvard Business School. I remember she came to see me one day. She said, 'Bob, you know, like 95% of the people who use it like it, and way, way less than 1% of people know it even exists.'
So she and Jill Bahr, who was the CEO at the time—later Grace became CEO—they said, 'Well, we have to find somebody who's going to have more appeal, certainly than me, to the general public.' So they got—and this would be my lesson if you do some non—things like cosmetics rather than medicine—but they got this young woman to be involved.
And actually later on we ended up selling the company to Unilever, and they quadrupled the size of the company and so forth. We also, at the time when we published this in Nature Materials, came up with a way where you could use certain materials to get rid of wrinkles. And we sold that part to Shiseido. Both are marketed—well, that's just marketed, I think, in Japan now. The other is marketed all over the world.
And so I thought I'd end on a couple of just notes. And the first one is just my observations as I think about being a professor. And that is, you know, of course the people in this audience, you are all the future. But what I really think is so important when you're in a university is, you know, up till the time you're maybe even a graduate student, you're totally judged by your tests. How good are your answers to somebody else's questions?
But really in life, you're going to be judged by the questions you ask. Are they important or are they not? And really, one of my goals is to help my students cross that bridge from being researchers who can give good answers to those who can ask good questions.
I also mentioned it's important to not give up easily. So about 27 years ago, I got this award, and I'll just—so many times when you try to do something in science, to try to find something, people will tell you it's impossible. And I think that's very rarely said. And if you really believe in yourself, really stick with it. But there's very little.
And lastly, you know, I think—and this is another piece of advice. This is actually from one of my postdocs that I didn't even realize that she said this, but my son saw it on LinkedIn, and I do say this—that really what's important is not how you do when things go well. Anybody can deal with success, but how do you deal with things when they go bad, like your NIH grant gets turned down or other things happen.
And so that's what I said: people can do great when things go well. It's what you do when things are not in your favor that makes a difference. This is Yung Yeo, who's a professor at Purdue. But those are just sort of little pieces of things that I've learned over the years. I want to thank you so much for listening to my struggles, for listening to what we've done. And anyhow, thank you so much for having me.
Host 58:01 ↗
Truly an inspiration. Maybe 20 years ago, the no-frizz would have helped me, but clearly not today.
Robert Langer 58:07 ↗
We have treatment.
Host 58:09 ↗
We'll talk about that. Please start thinking about your questions. There were some that I had for Bob and some that others had that I've written here. We'll get started, and then we'll take questions from the audience in a few minutes.
You've co-founded over 40 biotech companies, including Moderna. How do you balance—and this is a conversation we often have here—basic science discovery with entrepreneurship? And what advice would you give to particularly the young faculty getting started with balancing those two things?
Robert Langer 58:42 ↗
Yeah. Well, I have felt, and I look back, that I think when you're young and you start out, the most important thing to do first is to do a good job on being a professor—you know, to get your grants, to get your papers. I do think it's important to dream big dreams. So I would work on really what you feel are really important problems, and it could be not just inventing—I mean, I'm an engineer—but it could be discovering something, it could be understanding something better.
But to work on really important problems and do a great job on those and with your students over time, you know, as you get tenure and as you get promoted, I think doing the kind of thing that I mentioned, where you not only do that but you try to spin out companies, I think is very rewarding. It creates jobs for students.
I also think that it takes a long time. You know, it's easy. I can now look back over 51 years of doing this, and of course a lot of these things would mature. It takes a very long time to get things to a point where they're ready to get venture capital and they're ready to start companies.
So I think the other piece of advice I would give people, because it helps on funding, is to write patents. I think that writing patents on your work can only be helpful to you. And you might be surprised at what you do could be patentable. So many things are, but people don't necessarily think about it that way.
So I do think that if you write the patents, those patents could hopefully—you won't have a product no matter what you do right away, but later on, after a number of years, those patents may be useful to you. So those are a couple of things that I'd say.
And could you elaborate on—you mentioned the idea of how important it is to get a great CEO, and perhaps how scientists and engineers, academics, are not necessarily good at managing. Could you talk a little bit about that and how that's worked out?
Robert Langer 1:00:40 ↗
Obviously it's worked out very well. And that's a great question, and I brought that up specifically because I wouldn't want people to think—you know—I've had companies that have succeeded, I've had companies that have failed, and in neither case would I blame me for the failures or the successes, you know, because really the CEO—well, the CEO is such an important person, far, far more.
I mean, like I say, it wouldn't happen if we didn't get it started, but the CEO—to do these things, you have to raise enormous amounts of money, you have to think of the right business strategy, you have to hire people to do manufacturing, regulatory things, clinical trials, research, and you have to know a lot about all those things, and you have to listen to people.
Having a great CEO has been the number one thing. But beyond just a CEO, you want people who are good at operations, who are good at manufacturing, who are good at all these different things. So I mean, I think—I like to think I'm pretty good at judging scientists, and I even know after all this time something about intellectual property, but I always think that it's a partnership.
And I should say that not that many scientists or engineers have—you know, their different skill sets—and that's certainly not one that I feel I've had.
I want to talk a second about the mRNA vaccine. That has been one of the most transformative scientific achievements of our time, and you showed some of the data—the three million lives saved and the 1.5 trillion dollars. What was your reaction seeing your foundational work play such an important role around the world?
Robert Langer 1:02:27 ↗
Well, it was—you know—I've been working on these things for, like I say, by that time, almost 50 years now, longer than that. So it was—I mean, somebody thinks back to that time of November of 2020. I mean, it was a terrible year. We were all isolated at home. People were dying. It was wonderful to see that we could do something important to help people.
And so, you know, I don't think we knew. I remember being in the boardroom when we broke the code, you know, because it was a double-blind trial. So we broke the code, and you didn't know what it was going to be. And like I say, flu vaccines were 40 to 50%. So to see that this was 94%, that was, you know, remarkable.
Yeah. I want to talk about mentorship before we open it up soon. I mean, clearly people will talk about your patents and your discoveries and the impact you've had in saving lives. But I recall I was dean and I was provost, and I would hire a lot of faculty during my time here, and it seemed almost everybody that was in the bio space had some connection to you.
So you've mentored just hundreds, if not thousands, of the next generation of leaders. And you talked about at the end in terms of your philosophy. Talk a little bit about your philosophy with mentoring and why so many of your people that work with you are leaders themselves and doing incredible things. How did you do it?

16 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Langer, R. (2025, July 18). President's Lecture Series: Dr. Robert Langer [Interview transcript]. Rice University. CEOInterviews.AI. https://ceointerviews.ai/interview/3094502/

MLA

Robert Langer. "President's Lecture Series: Dr. Robert Langer." Rice University, 18 Jul. 2025. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3094502/.

BibTeX
@misc{langer2025_3094502,
  author       = {Robert Langer},
  title        = {President's Lecture Series: Dr.  Robert Langer},
  howpublished = {Interview transcript, Rice University. CEOInterviews.AI},
  year         = {2025},
  month        = {jul},
  url          = {https://ceointerviews.ai/interview/3094502/},
  note         = {Speaker-attributed transcript with timestamps}
}